Voriconazole, a second-generation triazole frequently used for the prophylaxis and
treatment of invasive fungal infections, undergoes complex metabolism mainly involving …

What is known and objectives Voriconazole is a triazole antifungal agent and is extensively
metabolized via cytochrome P450 (CYP 450); therefore, special precautions need to be …

Objectives Voriconazole exhibits non-linear pharmacokinetics in adults and is said to be
mainly metabolized by CYP2C19 and CYP3A4 to voriconazole-N-oxide. The aim of this …

Voriconazole is a broad-spectrum antifungal agent used for the treatment of severe fungal
infections. Maintaining therapeutic concentrations of 1 to 5.5 μg/ml is currently …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Pharmacokinetic variability of
voriconazole is largely caused by CYP3A4‐and CYP2C19‐mediated metabolism.• Oral …

Voriconazole is the first available second-generation triazole with potent activity against a
broad spectrum of clinically significant fungal pathogens, including Aspergillus, Candida …

Background Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is
mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to …

Aims Voriconazole is a new triazole antifungal agent, and is metabolized by the cytochrome
P450 isoenzymes CYP2C9, CYP2C19 and to a lesser extent by CYP3A4. Protease …

Background: Invasive mycoses are serious infections with high mortality and increasing
incidence. Voriconazole, an important drug to treat invasive mycosis, is metabolized mainly …

Background Voriconazole, a first-line antifungal drug, exhibits nonlinear pharmacokinetics
(PK), together with large interindividual variability but a narrow therapeutic range, and …